Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens Among HIV Infected Children and Adolescents in Tanzania

Overview

Journal J Int Assoc Provid AIDS Care

Publisher Sage Publications

Specialty Infectious Diseases

Date 2022 Jul 1

PMID 35776522

Authors

Ritah F Mutagonda

Hamu J Mlyuka

Betty A Maganda

Appolinary A R Kamuhabwa

Affiliations

Soon will be listed here.

Abstract

This study aimed at assessing adherence, effectiveness, and safety of DTG-based HAART regimens among HIV-infected children and adolescents in Tanzania. This was a single-center prospective cohort study, conducted at the pediatric HIV Clinic in Mbeya, Tanzania. A binary logistic regression model was used to determine predictors of undetectable viral load at week 24. The results were significant when P-value was <0.05. A total of 200 patients were enrolled with the majority (85.5%) being treatment experienced. High adherence levels (71%) were observed using the pharmacy refill method. At week 24, the overall proportion of patients with undetectable viral load was 70.2%. The predictors of undetectable viral load were age, World Health Organization (WHO) clinical stage, baseline VL and adherence to pharmacy refill. The majority of patients attained undetectable viral load 6 months after using DTG based regimen. DTG-based regimens were generally safe with few ADEs reported.

Citing Articles

Examining teen club attendance and viral load suppression among adolescents under differentiated HIV care in Malawi: a sub-optimal scenario.

Chamanga R, Musukwa T, Kalitera L, Gent F, Nkhoma H, Kudiabor K BMC Public Health. 2024; 24(1):3605.

PMID: 39736568 PMC: 11684046. DOI: 10.1186/s12889-024-21109-0.

Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania.

Majula R, Mweya C AIDS Res Ther. 2024; 21(1):98.

PMID: 39716209 PMC: 11667906. DOI: 10.1186/s12981-024-00662-z.

Viral suppression and adherence in adolescents living with HIV in rural Tanzania.

Luoga E, Okuma J, Moshi L, Sigalla G, Mnzava D, Paris D PLoS One. 2024; 19(12):e0315866.

PMID: 39705296 PMC: 11661625. DOI: 10.1371/journal.pone.0315866.

HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania.

Kamori D, Barabona G, Maokola W, Rugemalila J, Mahiti M, Mizinduko M PLoS One. 2024; 19(8):e0307003.

PMID: 39141647 PMC: 11324124. DOI: 10.1371/journal.pone.0307003.

Trends and correlates in HIV viral load monitoring and viral suppression among adolescents and young adults in Dar es Salaam, Tanzania.

Rugemalila J, Kunambi P, Amour M, Sambu V, Kisonjela F, Rugarabamu A Trop Med Int Health. 2024; 29(9):792-800.

PMID: 39097978 PMC: 11835364. DOI: 10.1111/tmi.14031.

References

Kanters S, Mills E, Thorlund K, Bucher H, Ioannidis J . Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses. Clin Microbiol Infect. 2013; 20(2):114-22. DOI: 10.1111/1469-0691.12475. View

Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T . Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2009; 54(1):254-8. PMC: 2798521. DOI: 10.1128/AAC.00842-09. View

Mghamba F, Minzi O, Massawe A, Sasi P . Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania. BMC Pediatr. 2013; 13:95. PMC: 3691638. DOI: 10.1186/1471-2431-13-95. View

Tabb Z, Mmbaga B, Gandhi M, Louie A, Kuncze K, Okochi H . Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. AIDS. 2018; 32(9):1115-1123. PMC: 5945296. DOI: 10.1097/QAD.0000000000001788. View

Lowenthal E, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand R . Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis. 2014; 14(7):627-39. PMC: 4074242. DOI: 10.1016/S1473-3099(13)70363-3. View

Fantauzzi A, Turriziani O, Mezzaroma I . Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl). 2013; 5:29-40. PMC: 3570074. DOI: 10.2147/HIV.S27765. View

Zanoni B, Mayer K . The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS. 2014; 28(3):128-35. PMC: 3948479. DOI: 10.1089/apc.2013.0345. View

Gelaw B, Mulatu G, Tesfa G, Marew C, Chekole B, Alebel A . Magnitude and associated factors of virological failure among children on ART in Bahir Dar Town public health facilities, Northwest Ethiopia: a facility based cross-sectional study. Ital J Pediatr. 2021; 47(1):84. PMC: 8025328. DOI: 10.1186/s13052-021-01030-7. View

Gupta A, Nadkarni G, Yang W, Chandrasekhar A, Gupte N, Bisson G . Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2012; 6(12):e28691. PMC: 3248405. DOI: 10.1371/journal.pone.0028691. View

10.

Rodriguez-Gonzalez C, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M . Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients. Ann Pharmacother. 2020; 54(7):633-643. DOI: 10.1177/1060028019896638. View

11.

Eron J, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A . Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2012; 207(5):740-8. PMC: 3563307. DOI: 10.1093/infdis/jis750. View

12.

Patel A, Patel K, Pujari S, Patel J, Kumar A . Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India. Indian J Sex Transm Dis AIDS. 2021; 42(1):31-37. PMC: 8579596. DOI: 10.4103/ijstd.IJSTD_34_20. View

13.

van Lunzen J, Maggiolo F, Arribas J, Rakhmanova A, Yeni P, Young B . Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2011; 12(2):111-8. DOI: 10.1016/S1473-3099(11)70290-0. View

14.

Boerma R, Boender T, Bussink A, Calis J, Bertagnolio S, Wit T . Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis. Clin Infect Dis. 2016; 63(12):1645-1654. DOI: 10.1093/cid/ciw645. View

15.

Nsheha A, Dow D, Kapanda G, Hamel B, Msuya L . Adherence to antiretroviral therapy among HIV-infected children receiving care at Kilimanjaro Christian Medical Centre (KCMC), Northern Tanzania: A cross- sectional analytical study. Pan Afr Med J. 2014; 17:238. PMC: 4145266. DOI: 10.11604/pamj.2014.17.238.2280. View

16.

Brehm T, Franz M, Hufner A, Hertling S, Schmiedel S, Degen O . Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients. Medicine (Baltimore). 2019; 98(32):e16721. PMC: 6708907. DOI: 10.1097/MD.0000000000016721. View

17.

Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S . Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381(9):816-826. DOI: 10.1056/NEJMoa1904340. View

18.

Haberer J, Kiwanuka J, Nansera D, Muzoora C, Hunt P, So J . Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013; 27(13):2166-8. PMC: 3868644. DOI: 10.1097/QAD.0b013e328363b53f. View

19.

Vreeman R, Nyandiko W, Liu H, Tu W, Scanlon M, Slaven J . Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya. J Int AIDS Soc. 2014; 17:19227. PMC: 4245448. DOI: 10.7448/IAS.17.1.19227. View

20.

Emmett S, Cunningham C, Mmbaga B, Kinabo G, Schimana W, Swai M . Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr. 2010; 54(4):368-75. PMC: 4185279. DOI: 10.1097/QAI.0b013e3181cf4882. View